

## For Immediate Release

Contact(s): Maryellen Bizzack  
Respironics, Inc.  
Director, Marketing &  
Communications  
724-387-5006

Brady Butler  
Blattner Brunner  
Sr. Account Executive  
412-995-9580

### **Respironics Breaks Ground on New \$32 Million Manufacturing Facility for Production of Sleep Therapy Devices**

**Murrysville, PA, Nov. 15, 2007 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP)** broke ground today on the Company’s new \$32 million manufacturing facility which will focus on the production of its sleep therapy devices. Public officials and community leaders took part in the ceremony which was held at the future site of the new 165,000-square-foot facility, located approximately seven miles from Respironics’ U.S. headquarters and current manufacturing site in Murrysville. Allen Kukovich, Director of the Governor’s Southwest Regional Office, presented Respironics with a ceremonial check representing a \$1.79 million economic package from the Department of Community and Economic Development of the Commonwealth of Pennsylvania.

Over the next three years Respironics’ ongoing expansion in southwestern Pennsylvania calls for capital investments of up to \$120 million in land, building, machinery and other equipment. The construction of the Company’s new sleep therapy facility represents a key phase in this expansion.

Respironics is pursuing LEED (Leadership in Energy and Environmental Design) certification for the building, reflecting its environmentally friendly design. Construction of the plant is expected to be completed in approximately 14 to 16 months. The project team includes WTW Architects, Bridges & Co., Inc., BDA Engineering, and Fahringer, McCarty, Grey Inc.

“Today is a celebration for Respironics as we break ground on our new world class manufacturing center dedicated to the production of sleep therapy devices,” said John L. Micolot, President and Chief Executive Officer. “This new facility will enable us to further the development of our center of excellence manufacturing strategy by focusing on products to support our Obstructive Sleep Apnea (OSA) business, a

#### **CORPORATE SERVICES**

1010 Murry Ridge Lane • Murrysville, PA 15668  
Phone 724.387.5200 • Fax 724.387.5010

core growth driver of the Company.” According to the National Sleep Foundation, more than 18 million Americans suffer from OSA, which is a cessation of breathing during sleep.

Respironics anticipates approximately 575 associates will be located at the new site, with anticipated workforce growth of 20% in five years. The current 125,000-square-foot manufacturing site will be used as a multi-purpose facility and continue production of ventilation and neonatal products used in the hospital and homecare markets. Since the current plant was constructed in 1990, Respironics has grown to a \$1.3 billion company with a presence in more than 141 countries. It operates manufacturing sites in Pennsylvania, California, Georgia, Connecticut, Oregon and abroad.

The new manufacturing site is one of several recent facility enhancements by Respironics to accommodate its growing operations and workforce. The company currently employs more than 1,700 associates in Western Pennsylvania and over 5,100 worldwide.

In 2007, Respironics marked the arrival of a new state-of-the-art facility in the United Kingdom for its European operations and Respiratory Drug Delivery (RDD) business and established a Center for Excellence in Aerosol Research. The company is also in the process of transitioning its RDD U.S. headquarters to new offices in Parsippany, NJ.

At its U.S. headquarters, Respironics expanded the footprint of its main campus with three nearby properties. It relocated its Sleep and Home Respiratory group to its new headquarters on Rt. 286 in Monroeville and celebrated the opening of a new 30,000-square-foot customer relations facility in Plum Borough. It also is developing new office space in Monroeville for its Children’s Medical Ventures business, which provides developmentally supportive products and services for premature babies, healthy newborns and older hospitalized infants.

The Company will not be changing its financial outlook or guidance based on this announcement.



## **About Respironics**

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and healthcare providers. Respironics markets its products in 141 countries and employs over 5,100 associates worldwide. Further information can be found on the Company's Web site: [www.respironics.com](http://www.respironics.com).

# # #

## **FORWARD-LOOKING STATEMENT**

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company's products and programs; the results of clinical trials; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major natural disaster, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company's stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

© 2007 Respironics, Inc. and its affiliates. All rights reserved.

## **CORPORATE SERVICES**

1010 Murry Ridge Lane • Murrysville, PA 15668  
Phone 724.387.5200 • Fax 724.387.5010